Previously, a humanized IgG1 monoclonal targeting CD22 (Epratuzumab) has undergone extensive evaluation as treatment for various subtypes of non-Hodgkin’s lymphoma (NHL) (Figure 5A). Here, CD22 is linked to non-Hodgkin lymphoma.